Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2011 June;53(2) > Panminerva Medica 2011 June;53(2):75-80

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

PANMINERVA MEDICA

Rivista di Medicina Interna


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,698


eTOC

 

ORIGINAL ARTICLES  


Panminerva Medica 2011 June;53(2):75-80

Copyright © 2011 EDIZIONI MINERVA MEDICA

lingua: Inglese

Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin

Karadag-Saygi E., Akyuz G.,Bizargity P, Ay P.

Physical Medicine and Rehabilitation, Marmara University School of Medicine, Instanbul, Turkey


PDF  


AIM: The aim of this study was to evaluate the effect of risedronate treatment on OPG, C-terminal cross-linking telopeptide of type 1 collagen (CTX), osteocalcin (OC), deoxypyridinoline (DPD), and to establish the correlation of OPG levels with other bone turnover markers.
METHODS. Eighty postmenopausal osteoporotic patients were randomized into two groups. In the first group, 37 patients received 35 mg of risedronate once a week, and 600 mg of elementary calcium with 400 IU of vitamin D per day. In the second group, 34 patients received only 600 mg of elementary calcium with 400 IU of vitamin D per day. OPG, OC, CTX and DPD levels were measured at baseline, then at 1, 3 and 6 months of treatment.
RESULTS: OPG levels were significantly reduced at 1 and 6 months of treatment in both the risedronate and control group (p<0.05, p<0.01, respectively), but no statistically significant difference was detected between the two groups (p>0.05). In the group treated with risedronate, a difference in CTX level was observed at 3 months of treatment, while a difference in DPD and OC levels were observed 6 months of treatment. The baseline OPG levels correlated with age, menopause duration and CTX levels. There was no correlation between OPG levels and the levels of the other markers.
CONCLUSION: Our results showed that using risedronate to treat postmenopausal osteoporosis causes no specific changes in OPG levels; thus, measurement of OPG levels as a marker may not be useful in the monitoring of bisphosphonate treatment.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

evrimkaradag4@hotmail.com